Hugel Inc Total Liabilities
Hugel Inc total liabilities. Based on the latest financial reports, Hugel Inc (145020) has total liabilities worth ₩104.15 Billion KRW (≈ $70.58 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Hugel Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Hugel Inc (2014–2025)
Total liabilities of Hugel Inc from 2014 to 2025. This chart illustrates how Hugel Inc's total liabilities have evolved over time, based on quarterly financial data. Explore 145020 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Hugel Inc Competitors by Total Liabilities
The table below lists competitors of Hugel Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KTK Group Co Ltd
SHG:603680
|
China | CN¥2.62 Billion |
|
SKAN Group AG
SW:SKAN
|
Switzerland | CHF353.49 Million |
|
Lotte Chemical Corp
KO:011170
|
Korea | ₩13.78 Trillion |
|
Zensar Technologies Limited
NSE:ZENSARTECH
|
India | Rs11.33 Billion |
|
ShanXi Coking Co Ltd
SHG:600740
|
China | CN¥10.15 Billion |
|
Shanghai Liangxin Electrical Co Ltd
SHE:002706
|
China | CN¥1.91 Billion |
|
Citic Offshore Helicopter Co Ltd
SHE:000099
|
China | CN¥1.90 Billion |
|
Jilin Chemical Fibre Co Ltd
SHE:000420
|
China | CN¥9.99 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Hugel Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 145020 asset base.
Liquidity & Leverage Metrics
Hugel Inc Total Liabilities Ratios Explained
Hugel Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hugel Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hugel Inc (2014–2025)
The table below shows the annual total liabilities of Hugel Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩96.68 Billion ≈ $65.52 Million |
-1.98% |
| 2024-12-31 | ₩98.63 Billion ≈ $66.84 Million |
-34.06% |
| 2023-12-31 | ₩149.57 Billion ≈ $101.36 Million |
-41.95% |
| 2022-12-31 | ₩257.67 Billion ≈ $174.62 Million |
+10.75% |
| 2021-12-31 | ₩232.65 Billion ≈ $157.66 Million |
+10.96% |
| 2020-12-31 | ₩209.67 Billion ≈ $142.09 Million |
+7.42% |
| 2019-12-31 | ₩195.19 Billion ≈ $132.28 Million |
+2.44% |
| 2018-12-31 | ₩190.55 Billion ≈ $129.13 Million |
+52.17% |
| 2017-12-31 | ₩125.22 Billion ≈ $84.86 Million |
+201.71% |
| 2016-12-31 | ₩41.50 Billion ≈ $28.13 Million |
+61.33% |
| 2015-12-31 | ₩25.73 Billion ≈ $17.43 Million |
-41.58% |
| 2014-12-31 | ₩44.04 Billion ≈ $29.84 Million |
-- |
About Hugel Inc
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults… Read more